Empagliflozin’s cardioenergetic protective effects through PPARα pathway modulation in heart failure
This study led to the following conclusions. 1) Rats with HF showed a significant increase in MRGlu compared with healthy rats. 2) Empagliflozin can improve the energy supply efficiency of the heart in rats with chronic HF by inhibiting glucose metabolism and promoting lipid metabolism, thereby ameliorating energy metabolism in chronic HF. 3) <sup>18</sup>F-FDG MicroPET/CT can observe the energy metabolism changes of HF, and the MRGlu can provide quantitative data for the changes of HF energy metabolism.
Authors
- Ming Yin
- Qin Zhou (ORCID: https://orcid.org/0000-0003-3879-4021)
- Jennifer Y. Chang (ORCID: https://orcid.org/0000-0002-2152-5071)
- Wei Hua (ORCID: https://orcid.org/0000-0002-3061-5749)
- Ping Wu (ORCID: https://orcid.org/0000-0002-7797-0828)
- Bo Feng (ORCID: https://orcid.org/0000-0002-4018-3257)
- Siyuan Chen (ORCID: https://orcid.org/0000-0002-3852-5617)
- Sijin Li (ORCID: https://orcid.org/0000-0003-0361-1248)
- Xirong Li (ORCID: https://orcid.org/0000-0003-0787-8230)
- Xiaoshan Guo
- Bao Li
Institutions
- Shanxi Medical University (CN)
- First Hospital of Shanxi Medical University (CN)
- Second Hospital of Shanxi Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-10-17
- DOI
- https://doi.org/10.3389/fphar.2025.1636810
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00